Probiotics and obesity associated disease: an extended view beyond traditional strains

Minerva Gastroenterol (Torino). 2021 Dec;67(4):348-356. doi: 10.23736/S2724-5985.21.02909-0.

Abstract

Interaction between intestinal microbiota and obesity is becoming abundantly according to current many scientific investigations. In this article, probiotic therapy was offered as the promising strategy of metabolic disorders control through the recovery of microbiota composition and health maintenance with the help of impact on the abovementioned mechanisms. First, this therapy is safe, with minimal side effects, well-tolerated, and appropriate for long-term use. Second, it can improve body mass, glucose, and fat metabolism, increase insulin sensitivity, and decrease systemic chronic inflammation. In conclusion, the restorative role of gut microbiota on metabolic disorders and associated diseases could open new ways in the treatment of obesity, insulin resistance, and type 2 diabetes.

MeSH terms

  • Diabetes Mellitus, Type 2* / therapy
  • Gastrointestinal Microbiome*
  • Humans
  • Insulin Resistance*
  • Obesity / therapy
  • Probiotics* / therapeutic use